QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Analyst Earnings Estimates
NASDAQ:QNRX - Nasdaq - US74907L4095 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 772.77% | N/A -14.00% | N/A 25.69% | N/A 59.07% | N/A 28.14% | ||||||||
| EBITDA YoY % growth | N/A | N/A | -8.014M | -6.045M 24.58% | -3.861M 36.12% | -5.959M -54.33% | -9.154M -53.61% | -9.275M -1.32% | -9.429M -1.66% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A -57.89% | -8.142M -17.49% | -6.271M 22.98% | -4.07M 35.09% | -6.063M -48.95% | -9.258M -52.69% | -9.379M -1.30% | -9.529M -1.60% | N/A -55.65% | N/A 18.39% | N/A 319.37% | N/A -16.47% | N/A 46.33% | N/A 95.14% | N/A 36.66% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A -64.36% | N/A | N/A | N/A | N/A | -2,977.80 88.57% | -358.40 87.96% | -81.20 77.34% | N/A 62.04% | N/A 53.67% | N/A 191.25% | N/A | N/A | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -6.86 58.29% | -7.14 41.74% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -3.962M -56.73% | -4.043M -68.09% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -6.28 53.99% | -7.56 | 1.28 | 16.91% |
| Q1 2025 Q2Q % growth | -6.50 83.27% | -6.19 | -0.31 | -5.04% |
| Q4 2024 Q2Q % growth | -12.25 83.17% | -16.42 | 4.17 | 25.40% |
| Q3 2024 Q2Q % growth | -16.45 75.90% | -17.61 | 1.16 | 6.60% |
| Q2 2024 Q2Q % growth | -13.65 81.69% | -21.78 | 8.13 | 37.32% |
| Q1 2024 Q2Q % growth | -38.85 72.79% | -27.13 | -11.72 | -43.19% |
| Q4 2023 Q2Q % growth | -72.80 57.72% | -82.65 | 9.85 | 11.91% |
| Q3 2023 Q2Q % growth | -68.25 82.71% | -97.18 | 28.93 | 29.77% |
| Q2 2023 Q2Q % growth | -74.55 94.52% | -100.67 | 26.12 | 25.95% |
| Q1 2023 Q2Q % growth | -142.80 86.40% | -121.10 | -21.70 | -17.92% |
| Q4 2022 Q2Q % growth | -172.20 95.44% | -264.75 | 92.55 | 34.96% |
| Q3 2022 Q2Q % growth | -394.80 71.64% | -577.48 | 182.68 | 31.63% |
| Q2 2022 Q2Q % growth | -1,360.80 | -1,320.92 | -39.88 | -3.02% |
| Q1 2022 Q2Q % growth | -1,050.00 | -1,419.08 | 369.08 | 26.01% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -17.62% | 0% | 15.56% |
| Revenue | N/A | N/A | N/A | N/A |